These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

535 related items for PubMed ID: 26514544

  • 21. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
    Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, Elena C, Gallì A, Walldin G, Della Porta MG, Raaschou-Jensen K, Travaglino E, Kallenbach K, Pietra D, Ljungström V, Conte S, Boveri E, Invernizzi R, Rosenquist R, Campbell PJ, Cazzola M, Hellström Lindberg E.
    Blood; 2015 Jul 09; 126(2):233-41. PubMed ID: 25957392
    [Abstract] [Full Text] [Related]

  • 22. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
    Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A.
    Am J Hematol; 2013 Mar 09; 88(3):201-6. PubMed ID: 23335386
    [Abstract] [Full Text] [Related]

  • 23. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
    Wang X, Song X, Yan X.
    Medicine (Baltimore); 2019 May 09; 98(21):e15743. PubMed ID: 31124956
    [Abstract] [Full Text] [Related]

  • 24. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM, Yoo NJ, Kim YJ, Kim MS, Lee SH.
    Int J Cancer; 2013 Jul 09; 133(1):260-5. PubMed ID: 23280334
    [Abstract] [Full Text] [Related]

  • 25. Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).
    Tefferi A, Idossa D, Lasho TL, Mudireddy M, Finke C, Shah S, Nicolosi M, Patnaik MM, Pardanani A, Gangat N, Hanson CA, Ketterling RP.
    Blood Cancer J; 2017 Dec 18; 7(12):658. PubMed ID: 29249799
    [No Abstract] [Full Text] [Related]

  • 26. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, Godwin A, Pessetto Z, Golem S, Divine C, Dias A.
    Leuk Res; 2020 Aug 18; 95():106402. PubMed ID: 32590108
    [Abstract] [Full Text] [Related]

  • 27. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
    Wu L, Song L, Xu L, Chang C, Xu F, Wu D, He Q, Su J, Zhou L, Xiao C, Zhang Z, Zhao Y, Chen S, Li X.
    Tumour Biol; 2016 Apr 18; 37(4):4633-40. PubMed ID: 26508027
    [Abstract] [Full Text] [Related]

  • 28. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
    Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, Hanna R, Kalaycio M, Sekeres MA, Sobecks R, de Lima M, Majhail NS, Maciejewski J.
    Bone Marrow Transplant; 2019 Aug 18; 54(8):1281-1286. PubMed ID: 30655603
    [Abstract] [Full Text] [Related]

  • 29. Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases.
    Farrukh F, Abdelmagid M, Mangaonkar A, Patnaik M, Al-Kali A, Elliott MA, Begna KH, Hook CC, Hogan WJ, Pardanani A, Litzow MR, Ketterling RP, Gangat N, Arber DA, Orazi A, He R, Reichard K, Tefferi A.
    Haematologica; 2024 Aug 01; 109(8):2525-2532. PubMed ID: 38450522
    [Abstract] [Full Text] [Related]

  • 30. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.
    McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L.
    Haematologica; 2016 Aug 01; 101(8):e320-3. PubMed ID: 27081179
    [No Abstract] [Full Text] [Related]

  • 31. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G.
    Cancer; 2020 Feb 15; 126(4):765-774. PubMed ID: 31742675
    [Abstract] [Full Text] [Related]

  • 32. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
    Hirabayashi S, Flotho C, Moetter J, Heuser M, Hasle H, Gruhn B, Klingebiel T, Thol F, Schlegelberger B, Baumann I, Strahm B, Stary J, Locatelli F, Zecca M, Bergstraesser E, Dworzak M, van den Heuvel-Eibrink MM, De Moerloose B, Ogawa S, Niemeyer CM, Wlodarski MW, European Working Group of MDS in Childhood.
    Blood; 2012 Mar 15; 119(11):e96-9. PubMed ID: 22238327
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y, Li X, Chang C, Xu F, He Q, Guo J, Tao Y, Liu Y, Liu L, Shi W.
    Leuk Res; 2016 May 15; 44():8-16. PubMed ID: 26970172
    [Abstract] [Full Text] [Related]

  • 35. Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms.
    Ma Q, Liu Y, Zhao H, Guo Y, Sun W, Hu R.
    Hematology; 2024 Dec 15; 29(1):2387878. PubMed ID: 39140716
    [Abstract] [Full Text] [Related]

  • 36. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D.
    Oncotarget; 2015 Apr 10; 6(10):8388-96. PubMed ID: 25860933
    [Abstract] [Full Text] [Related]

  • 37. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA.
    J Hematol Oncol; 2015 May 08; 8():45. PubMed ID: 25952993
    [Abstract] [Full Text] [Related]

  • 38. Prognostic impact of DTA mutation and co-occurring mutations in patients with myelodysplastic syndrome.
    Wang M, Chen P, Li D, Zhao M.
    Mol Biol Rep; 2024 Sep 15; 51(1):985. PubMed ID: 39278886
    [Abstract] [Full Text] [Related]

  • 39. Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Dutta S, Moritz J, Pregartner G, Thallinger GG, Brandstätter I, Lind K, Rezania S, Lyssy F, Reinisch A, Zebisch A, Berghold A, Wölfler A, Sill H.
    Ann Hematol; 2022 Apr 15; 101(4):837-846. PubMed ID: 35083527
    [Abstract] [Full Text] [Related]

  • 40. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
    Tefferi A, Fleti F, Chan O, Al Ali NH, Al-Kali A, Begna KH, Foran JM, Badar T, Khera N, Shah M, Hiwase D, Padron E, Sallman DA, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R.
    Br J Haematol; 2024 Apr 15; 204(4):1243-1248. PubMed ID: 38083865
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.